

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark J. Fields and Richard :  
G. Williams

APPLICATION NO.: 10/598,712 : Examiner: MAEWALL,  
SNIGDHA

FILING DATE: September 12, 2006 : Group Art Unit: 1612

TITLE: COMBINATIONS COMPRISING :  
ALPHA-2-DELTA LIGANDS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a form conforming with PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed.

- 1) US 6,372,792B1 (CHOUGINARD GUY) 16 April 2002
- 2) US 4,831,031A
- 3) US 6,245,766 B1
- 4) US Serial No. 10/845,826; filed May 14, 2004; Romano; currently pending
- 5) US 4,024,175
- 6) WO 03/035040 A (DEPOMED, INC) 1 MAY 2003
- 7) WO 2004/016259 A (PFIZER LIMITED; FIELD, MARK, JOHN; WILLIAMS, RICHARD, GRIFFITH; PFIZER) 26 February 2004
- 8) WO 2004/006836 A (MERCK & CO., INC; ANKER, NAOMI BURKE; ARRUDA, JEANINE, M; CAMPBELL, BR) 22 January 2004 (2004-01-22)
- 9) WO 2004/100992 A (PFIZER PRODUCTS INC; ROMANO, STEVEN, JOSEPH) 25 November 2004
- 10) WO 01/28978A
- 11) WO 99/31075A

- 12) WO 98/03167A
- 13) WO 02/085839A
- 14) WO 2004/039367
- 15) WO 99/21824
- 16) WO 2003/082807
- 17) WO 02/19213A
- 18) EP 641330
- 19) EP 0934061
- 20) EP 1129706A
- 21) PRIDMORE S ET AL: "WILL THE ATYPICAL ANTIPSYCHOTICS BE ANALGESICS?" AUSTRALASIAN PSYCHIATRY, BLACKWELL SCIENCE, CARLTON, AU, vol.11, no. 1, March 2003 (2003-03), pages 59-61, XP008040570 ISSN: 1039-8562
- 22) USISKIN S I ET AL: "GABAPENTIN PROPHYLAXIS OF CLOZAPINE-INDUCED SEIZURES [3]" AMERICAN JOURNAL OF PSYCHIATRY 2000 UNITED STATES, vol. 157, no.3, 2000, pages 482-483, XP002327830 ISSN: 0002-953X
- 23) SELAK I: "PREGABALIN (PFIZER)." CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND: 2000) ENGLAND JUN 2001, VOL. 2, NO. 6, JUNE 2001 (2001-06), PAGES 828-834, XP009020712 ISSN: 1472-4472; THE WHOLE DOCUMENT.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). WO 99/21824 (reference 15 above) and WO 2003/082807 (reference 16 above) disclose the elected alpha-2-delta ligands.

It is requested that the references listed on the attached form conforming with PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 6, 2008

/Kristina L. Konstas/  
Kristina L. Konstas  
Attorney for Applicants  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -6380